Bioactive glycosides from the African medicinal plant Boerhavia erecta L.

Ari Satia Nugraha  
*University of Wollongong, asn559@uowmail.edu.au*

Adama Hilou  
*Universite de Ouagadougou*

Nicholas Vandegraaff  
*Avexa Ltd*

David I. Rhodes  
*University of Wollongong, drhodes@uow.edu.au*

Rachada Haritakun  
*National Science and Technology Development Agency, Thailand*

*See next page for additional authors*
Bioactive glycosides from the African medicinal plant Boerhavia erecta L.

Abstract
Phytochemical studies of the previously unexplored stem of Boerhavia erecta from Burkina Faso, resulted in the isolation of an unreported glycoside 4, 2,3-dihydroxypropylbenzoate-3-O-β-[4”-methoxy] glucuronide as well as seven known glycosides (1-3, 5-8). The major isolate 5 and 8 indicated a significant inhibition against HIV integrase (IC50 10 and 22 μg/mL, respectively). The extracts and isolates were also tested for antimalarial activity, but insignificant activity was observed.

Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences

Publication Details

Authors
Ari Satia Nugraha, Adama Hilou, Nicholas Vandegraaff, David I. Rhodes, Rachada Haritakun, and Paul A. Keller

This journal article is available at Research Online: http://ro.uow.edu.au/smhpapers/3183
Bioactive glycosides from the African medicinal plant *Boerhavia erecta* L.

Ari S. Nugraha\textsuperscript{a}, Adama Hilou\textsuperscript{b*}, Nicholas Vandegraaff\textsuperscript{c}, David I. Rhodes\textsuperscript{c}, Rachada Haritakund\textsuperscript{d} and Paul A. Keller\textsuperscript{a*}

\textsuperscript{a}School of Chemistry, University of Wollongong, Wollongong, New South Wales, Australia 2522.
\textsuperscript{b}Département de biochimie-microbiologie, UFR/VT, Université de Ouagadougou, Burkina Faso, Africa 03
\textsuperscript{c}Avexa Limited, 576 Swan St, Richmond, Victoria, Australia 3121
\textsuperscript{d}National Centre for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), 113 Phaholyothin Road, Klong1, Klong Luang, Pathumanthani 12120 Thailand

*corresponding authors:
Paul A. Keller, School of Chemistry, University of Wollongong, Northfields Ave, Wollongong, NSW, 2522, Australia, keller@uow.edu.au, tele +61 2 4221 4692, fax +61 2 4221 4287.

**Abstract**

Phytochemical studies of the previously unexplored stem of *Boerhavia erecta* from Burkina Faso-Africa, resulted in the isolation of an unreported glycoside 4, 2,3-dihydroxypropylbenzoate-3-O-\(\beta\)-[4"-methoxy] glucuronide as well as seven known glycosides (1-3, 5-8). The major isolate 5 and 8 indicated a significant inhibition against HIV-integrase (IC\textsubscript{50} 10 and 22 \(\mu\)g/mL, respectively). The extracts and isolates were also tested for anti-malarial activity but insignificant activity was observed.

**Keywords:** African medicinal plant, *Boerhavia erecta*, Glycosides, Anti-HIV integrase activity, Anti-malarial activity

**1. Introduction**

Burkina Faso is a country rich with medicinal plants including prospective medical sources of the *Boerhavia erecta* Linnaeus species which the aerial component of the plant is used in traditional medicine for the treatment of nervous malaria in infants, seizures in children, generalized edema, dyspnea, difficult delivery, hematuria, as an anti-convulsant, diuretic or spasmyloytic (Hilou et al., 2004). Previous studies on the extract of the leaves of *B. erecta* revealed some activities, including antimicrobial (Perumal Samy et al., 1999) and anti-malarial effects (Hilou et al., 2004; Hilou et al., 2006; Stinzing et al., 2004). This led to the isolation of sterols and betanin (Stinzing et al., 2004; Miralles et al., 1988). The previous investigation was driven mainly by the isolation of phenolic compounds from the leaves of the plant for anti-oxidant studies (Petrus et al., 2012). Here, we report for the first time the results of the stem bark of this plant and the bioactive constituents of polar fraction of this plant.
2. Result and discussion

The non-polar alkanes and long chain fatty acids of the crude extract were removed by applying solid liquid (hexane, dichloromethane) back extraction. From the polar fraction, short normal phase column chromatography produced a major fraction which was subjected to preparative HPLC, isolating eight compounds (Figure 1): 3-methoxybenzoic acid 4-\(O-\beta\)-glucoside \(1\) (Liu et al., 2006), 3-methoxyacetophenone 4-\(O-\beta\)-glucopyranoside \(2\) (Rosa et al., 1996), isorhamnetin-3-O-rutinoside-7-\(O-\beta\)-glucopyranoside \(3\) (Aquino et al., 1987), quercetin-3-O-rutinoside \(5\), quercetin-3-\(O-\beta\)-glucopyranoside \(6\), kaemferol-3-O-rutinoside \(7\) (Hamzah et al., 1998), and isorhamnetin-3-O-rutinoside \(8\). Compounds \(5\), \(6\) and \(8\) were previously reported from the leaves of the plant (Petrus et al., 2012), and are spectroscopically identical to that reported. Importantly, compounds \(1\) – \(3\) and \(7\) were isolated from this plant for the first time in this study.

![Molecular structure of glycosides](image)

**Figure 1.** Molecular structure of glycosides isolated from stem of *Boerhavia erecta*. Compound \(9\) was isolated from *V. hookeriana* (Maggi et al, 2009).

Additionally, for the previously unreported compound, we propose the structure \(4\) (Figure 2). The HRESI MS analysis of \(4\) indicated a peak at \(m/z\) 409.1107 ([M+Na]\(^{+}\)), assigned to the molecular formula of \(C_{17}H_{22}O_{10}Na\). The NMR spectral analysis suggested a molecular structure which was similar to a reported glycerol \(\alpha\)-D-glucuronide carboxylic acid (Cai et al., 2011) and its ester \(9\) (Maggi et al., 2009). The \(^1H\)- and \(^{13}C\)-NMR spectral analysis indicated a singlet peak at \(\delta\) 3.46 and \(\delta\) 60.8 ppm, respectively, assigned to a methoxy group; this was in contrast to the corresponding ester OMe in \(9\) with values assigned in the \(^1H\)- and \(^{13}C\)-NMR spectra of \(\delta\) 3.66 and \(\delta\) 52.8 ppm, respectively (Maggi et al, 2009). This is particularly telling with the 8.0 ppm difference in the OMe in the \(^{13}C\) NMR spectrum, with the methoxy ester more upfield compared to the methoxy substituent, as expected. gHMBC spectral analysis of \(4\) indicated a proton-carbon correlation between the methoxy and carbon peak at \(\delta\) 83.0 (assigned to \(C4''\) of the sugar moiety). Additionally, a 3-bond correlation between H4" and the
carbonyl was evident. Thus the molecular structure for 4 is proposed as 2,3-dihydroxypropyl-benzoate 3-O-β-[4"-methoxy] glucuronide. The position of the benzoic ester carbonyl peak in the $^{13}$C NMR spectrum was consistent across all three derivatives (~168 ppm).

![Figure 2: Proposed structure of 4 and the known α-D-glucuronide carboxylates 9 and 10. Key NMR assignments are indicated (single-headed arrows) while key HMBC correlations (double-headed arrows) are also shown. For a larger set of correlations for 4, see SI.](image)

Preliminary studies on the crude extract revealed significant inhibition activity against HIV integrase in which ‘fraction B’ (the extract residue) showed a higher activity than the supernatant (fraction A). Further assays on the major constituents, compounds 5 and 8, indicated moderate and less activity compared to the original extract (Table 1). The isolates were also tested against *P. falciparum* K1 which showed no significant activity (Table 1). The isolated compounds showed less inhibition relative to the fractions with the HIV integrase activity testing. This suggests a synergic mechanism playing an important role in the bioactivity. Fractions, sub-fractions, and compounds 1 - 8 were inactive against *P. falciparum* K1 (Table 1).
Table 1. Anti-HIV integrase and anti-plasmodial activities (IC$_{50}$ in μg/mL) of the extracts and pure compounds isolated from *B. erecta*

<table>
<thead>
<tr>
<th>Entry</th>
<th>Anti-HIV integrase activity</th>
<th>Anti-malarial activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IC$_{50}$ (μg/mL)</td>
<td>Activity</td>
</tr>
<tr>
<td>Crude extract</td>
<td>&lt; 1.6</td>
<td>na</td>
</tr>
<tr>
<td>Fraction A</td>
<td>16</td>
<td>inactive</td>
</tr>
<tr>
<td>Fraction B</td>
<td>&lt; 0.4</td>
<td>inactive</td>
</tr>
<tr>
<td>Fraction B1</td>
<td>&lt; 10</td>
<td>na</td>
</tr>
<tr>
<td>Fraction B2</td>
<td>&lt; 46</td>
<td>na</td>
</tr>
<tr>
<td>Fraction B4</td>
<td>&gt; 50</td>
<td>na</td>
</tr>
<tr>
<td>5</td>
<td>&lt; 10</td>
<td>inactive</td>
</tr>
<tr>
<td>8</td>
<td>&lt; 22</td>
<td>inactive</td>
</tr>
</tbody>
</table>

Note: na: data not available. -: No activity. Compounds 1-4, 6 and 7 were inactive against *P. falciparum* K1 and were not tested against HIV integrase. Anti-malarial testing, final conc. of samples: 10 μg/mL Negative control: 0.1% DMSO. IC$_{50}$ of positive control: Dihydroartemisinine = 2.20 nM, Mefloquine = 0.0310 μM.

Quercetin has been reported to inhibit HIV infected cells (Tang et al., 1994), which were later found to have diverse modes of action including anti-protease (PR), anti-integrase (IN) and anti-transcriptase (RT) activities. Quercetin and rutin revealed inhibition against HIV-1 protease with IC$_{50}$ values of 34 and 28 μg/mL, respectively, although methoxylation or glucosylation at 3,7,4' reduced its activity (Xu et al., 2000). Quercetin was a weak HIV-1 RT inhibitor (IC$_{50}$ 150-200 μg/mL) possibly due to structural planarity which weakens its intercalating properties (Tan et al., 1991) however, glucosylation at 3' increased the activity (IC$_{50}$ 15 μg/mL). Quercetin possessed anti-integrase activity with IC$_{50}$ of 4 μg/mL) (Raghavan et al., 1995).

3. Conclusions
A previously unreported derivative of the glycerol α-D-glucuronide class of compounds (4) was isolated from the stem of *B. erecta* which was proposed as 2,3-dihydroxypropylbenzoate 3-O-β-[4''-methoxy] glucuronide. Moderate anti-HIV integrase activity was shown the by major constituents (5 and 8). The anti-malarial testing against *P. falciparum* K1 indicated none of the purified compounds possessed anti-plasmodial activity. However, the major compounds 5 and 8 were previously reported to have anti-malarial activity *P. falciparum* (FCR3, cycloguanil-resistant from Gambia) (Murakami et al., 2001). Therefore, these compounds show significant differences in their *P. falciparum* inhibitory activity between different strains.

Supplementary data: Experimental details relating to this article are available online; $^1$H, $^{13}$C, COSY, gTOCSY, HSQC, HMBC, HR ESI MS and MS/MS spectra of compounds 4.
Acknowledgments - ASN thanks the Australian Government for an ADS (AusAid) Scholarship and the University of Wollongong for University Postgraduate Scholarships.

References


